(NASDAQ: ALT) Altimmune's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.
Altimmune's earnings in 2026 is -$83,915,000.On average, 10 Wall Street analysts forecast ALT's earnings for 2026 to be -$129,483,683, with the lowest ALT earnings forecast at -$169,600,689, and the highest ALT earnings forecast at -$112,750,888. On average, 7 Wall Street analysts forecast ALT's earnings for 2027 to be -$116,003,618, with the lowest ALT earnings forecast at -$200,251,415, and the highest ALT earnings forecast at -$20,798,708.
In 2028, ALT is forecast to generate $315,546,105 in earnings, with the lowest earnings forecast at -$199,229,725 and the highest earnings forecast at $1,207,419,705.